Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 8/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.97 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | GAA | P10253 | 1/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.90 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21051754 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL26511991 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL13367139 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL17109729 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL19040665 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL10498260 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL17100575 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL34571 | 0.99 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL20658960 | 0.97 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL20658962 | 0.97 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060120980-A1 | Novel dermatological composition using bio-activating organocatalysts | EBERSYTES, LLC | 2006-06-08 | — | — | US | claimed |
| EP-1648376-A2 | NOVEL DERMATOLOGICAL COMPOSITION | Ebersytes, LLC (US) | 2006-04-26 | — | — | EP | claimed |
| EP-1530720-A4 | BREAST CANCER ERADICATION PROGRAM | SIRBASKU DAVID A (US) | 2005-08-31 | — | — | EP | claimed |
| EP-1530720-A2 | BREAST CANCER ERADICATION PROGRAM | Sirbasku, David A. (US) | 2005-05-18 | — | — | EP | claimed |
| WO-2005000224-A2 | NOVEL DERMATOLOGICAL COMPOSITION | EBERSYTES, LLC (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040247633-A1 | Novel dermatological composition | EBERSYTES, LLC | 2004-12-09 | — | — | US | claimed |
| WO-2003042404-A2 | BREAST CANCER ERADICATION PROGRAM | SIRBASKU DAVID A (US) | 2003-05-22 | — | — | WO | claimed |
| US-20030072812-A1 | Breast cancer eradication program | SIGNE BIOPHARMA INC. | 2003-04-17 | — | — | US | claimed |
| US-20250037787-A1 | CONCENTRATION BOUNDS IN LARGE NETWORKS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-01-30 | — | — | US | disclosed |
| US-20230158177-A1 | HYPOXIA-TARGETING CONTRAST AGENT AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
| CN-114349801-B | Technetium-99 m labeled isopenitrile-containing fenoxamine derivative, and preparation method and application thereof | 北京师范大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-114349801-A | Technetium-99 m labeled isopenitrile-containing fenoxamine derivative, and preparation method and application thereof | 北京师范大学 | 2022-04-15 | — | — | CN | disclosed |
| EP-3105198-B1 | SOIL BACTERIA FOR INOCULATING STRESS SOILS | BIOFIL MIKROBIOLOGIAI GENTECHNOLOGIAI ES BIOKEMIAI KFT (HU) | 2022-02-16 | — | — | EP | disclosed |
| CN-107281498-A | Iron ion chelating agent modified by polyethylene glycol | 四川大学华西医院 | 2017-10-24 | — | — | CN | disclosed |
| US-20040247633-A1 | Novel dermatological composition | EBERSYTES, LLC | 2004-12-09 | — | — | US | disclosed |
| CN-1331971-A | New application of deferiprone | APTEX INC (CA) | 2002-01-23 | — | — | CN | disclosed |
| EP-0553273-A4 | POLYMER-DEFEROXAMINE-FERRIC IRON ADDUCTS FOR USE IN MAGNETIC RESONANCE IMAGING | BIOMED FRONTIERS INC (US) | 1998-04-22 | — | — | EP | disclosed |
| US-5268165-A | Administering a diagnostic contrast agent | BIOMEDICAL FRONTIERS, INC. (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0553273-A1 | POLYMER-DEFEROXAMINE-FERRIC IRON ADDUCTS FOR USE IN MAGNETIC RESONANCE IMAGING | BIOMEDICAL FRONTIERS, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992007259-A1 | POLYMER-DEFEROXAMINE-FERRIC IRON ADDUCTS FOR USE IN MAGNETIC RESONANCE IMAGING | BIOMEDICAL FRONTIERS, INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060120980-A1 | Novel dermatological composition using bio-activating organocatalysts | FGF1, FGF2, FGFR3 | KDM4A 3738/4885HIF1A 2713/4885TET2 3573/4885 |
| US-20230158177-A1 | HYPOXIA-TARGETING CONTRAST AGENT AND METHODS OF USE THEREOF | HIF1AN, HIF1A, HYOU1 | KDM4A 2855/4885HIF1A 2/4885TET2 4017/4885 |
| US-20040247633-A1 | Novel dermatological composition | FGF2, FGF1, KRT18 | KDM4A 3316/4885HIF1A 1762/4885TET2 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.